Breye Therapeutics

Breye Therapeutics announced €67.5M in Series A financing on September 29, 2026. Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.

Round details

The financing includes backing from Mission BioCapital, Novo Holdings, Sound Bioventures, Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, Pappas Capital. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: €67.5M

How the company plans to use the capital

Breye will use the proceeds to advance its lead asset danegaptide into a randomized Phase 2 clinical trial in patients with non-proliferative diabetic retinopathy, which the company said is due to start in 2027. The funding will also be used to progress its broader pipeline of oral small molecules.

Why this matters for GTM teams

Breye describes itself as a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal eye diseases, and calls danegaptide the first oral drug designed to treat diabetic retinopathy in its earlier stages.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Breye Therapeutics Series A announcement.